Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
Go back to Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management| Abbott Laboratories (NYSE: ABT) | Delayed: 94.12 +0.88 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $93.24 | 52 Week High | $46.38 | |||
| Open | $93.86 | 52 Week Low | $36.00 | |||
| Day High | $95.21 | P/E | 62.75 | |||
| Day Low | $93.21 | EPS | $1.50 | |||
| Volume | 16,464,988 | |||||
